Eupafolin exhibits potent anti-angiogenic and antitumor activity in hepatocellular carcinoma

International Journal of Biological Sciences

Volumn 13, Issue 6, 2017, Pages 701-711

  Jiang, Honglei ^a   Wu, Dan ^a   Xu, Dong ^a   Yu, Hao ^a   Zhao, Zheming ^a   Ma, Dongyan ^a   Jin, Junzhe ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Eupafolin; Tumor angiogenesis

Indexed keywords

EUPAFOLIN; FLAVONE DERIVATIVE; VASCULOTROPIN A;

ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FLAVONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020175521     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.17534     Document Type: Article

References (44)

1. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146: 873-87.
2. Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 1-18.
3. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2: 795-803.
4. Bishayee A, Darvesh AS. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy. Curr Cancer Drug Targets. 2012; 12: 1095-118.
5. Domigan CK, Iruela-Arispe ML. Recent advances in vascular development. Curr Opin Hematol. 2012; 19: 176-83.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-76.
7. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932-6.
8. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006; 13: 63-9.
9. Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. Curr Pharm Des. 2014; 20: 2834-42.
10. Hu TH, Huang CC, Wu CL, Lin PR, Liu SY, Lin JW, et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol. 2005; 18: 663-72.
11. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, et al. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol. 2011; 64: 343-8.
12. Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol. 2004; 10: 1533-6.
13. Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014; 3: 9-17.
14. Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol. 2014; 20: 3087-99.
15. Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther. 2015; 9: 352-62.
16. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8: 292-301.
17. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012; 39: 486-92.
18. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10: 417-27.
19. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J Med Chem. 2008; 51: 2589-99.
20. Clavin M, Gorzalczany S, Macho A, Munoz E, Ferraro G, Acevedo C, et al. Anti-inflammatory activity of flavonoids from Eupatorium arnottianum. J Ethnopharmacol. 2007; 112: 585-9.
21. Lai ZR, Ho YL, Huang SC, Huang TH, Lai SC, Tsai JC, et al. Antioxidant, anti-inflammatory and antiproliferative activities of Kalanchoe gracilis (L.) DC stem. Am J Chin Med. 2011; 39: 1275-90.
22. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med. 2012; 16: 2321-30.
23. Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem. 1999; 274: 35562-70.
24. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008; 7: 1789-96.
25. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-32.
26. Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol. 2014; 20: 4151-9.
27. Mazzoccoli G, Miele L, Oben J, Grieco A, Vinciguerra M. Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. Curr Drug Targets. 2016; 17: 783-99.
28. Liu K, Park C, Chen H, Hwang J, Thimmegowda NR, Bae EY, et al. Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling. Mol Carcinog. 2015; 54: 751-60.
29. Chung KS, Choi JH, Back NI, Choi MS, Kang EK, Chung HG, et al. Eupafolin, a flavonoid isolated from Artemisia princeps, induced apoptosis in human cervical adenocarcinoma HeLa cells. Mol Nutr Food Res. 2010; 54: 1318-28.
30. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-10.
31. Moserle L, Amadori A, Indraccolo S. The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med. 2009; 9: 935-41.
32. Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, et al. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology. 2014; 60: 1264-77.
33. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-62.
34. Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, et al. TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013; 73: 6938-50.
35. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 2004; 15: 4841-53.
36. Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, et al. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res. 2008; 18: 780-91.
37. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001; 276: 38349-52.
38. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, Feng J, Brodbeck D, Perentes E, et al. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem. 2003; 278: 32124-31.
39. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem. 2004; 279: 45643-51.
40. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001; 98: 10983-5.
41. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A. 2001; 98: 6074-9.
42. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001; 61: 5911-8.
43. Kang S, Bader AG, Zhao L, Vogt PK. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle. 2005; 4: 578-81.
44. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008; 8: 19-26.